Guillaume Vogt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1529178/publications.pdf

Version: 2024-02-01

37 papers 3,688 citations

28 h-index 288905 40 g-index

43 all docs 43 docs citations

times ranked

43

5399 citing authors

#	Article	IF	CITATIONS
1	Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. Journal of Clinical Immunology, 2021, 41, 639-657.	2.0	30
2	Systemic Modelling in Bioethics. New Bioethics, 2020, 26, 197-209.	0.5	6
3	Frenchâ€style genetics v. 2.0: The "eâ€CohortE―project. Clinical Genetics, 2019, 96, 330-340.	1.0	5
4	Genetic Data, Two-Sided Markets and Dynamic Consent: United States Versus France. Science and Engineering Ethics, 2019, 25, 1597-1602.	1.7	8
5	Artificial intelligence in internal medicine: Between science and pseudoscience. European Journal of Internal Medicine, 2018, 51, e33-e34.	1.0	9
6	Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine. Science and Engineering Ethics, 2018, 24, 307-322.	1.7	29
7	IRF4 haploinsufficiency in a family with Whipple's disease. ELife, 2018, 7, .	2.8	43
8	Glycosylation-Dependent IFN-γR Partitioning in Lipid and Actin Nanodomains Is Critical for JAK Activation. Cell, 2016, 166, 920-934.	13.5	110
9	Whole-exome sequencing to analyze population structure, parental inbreeding, and familial linkage. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6713-6718.	3.3	53
10	23andMe: a new two-sided data-banking market model. BMC Medical Ethics, 2016, 17, 19.	1.0	53
11	Mycobacterial disease in patients with chronic granulomatous disease: AÂretrospective analysis of 71 cases. Journal of Allergy and Clinical Immunology, 2016, 138, 241-248.e3.	1.5	106
12	Mycobacterium simiae Infection in Two Unrelated Patients with Different Forms of Inherited IFN-Î ³ R2 Deficiency. Journal of Clinical Immunology, 2014, 34, 904-909.	2.0	20
13	Partial IFN- \hat{l}^3 R2 deficiency is due to protein misfolding and can be rescued by inhibitors of glycosylation. Blood, 2013, 122, 2390-2401.	0.6	34
14	Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Human Molecular Genetics, 2013, 22, 769-781.	1.4	58
15	The human gene connectome as a map of short cuts for morbid allele discovery. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5558-5563.	3.3	79
16	Mycobacterial Disease and Impaired IFN-γ Immunity in Humans with Inherited ISG15 Deficiency. Science, 2012, 337, 1684-1688.	6.0	455
17	Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nature Immunology, 2011, 12, 213-221.	7.0	248
18	Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. Journal of Experimental Medicine, 2011, 208, 2083-2098.	4.2	262

#	Article	IF	Citations
19	In vitro differentiation of human macrophages with enhanced antimycobacterial activity. Journal of Clinical Investigation, 2011, 121, 3889-3901.	3.9	91
20	A novel form of cell type-specific partial IFN- \hat{l}^3 R1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. Human Molecular Genetics, 2010, 19, 434-444.	1.4	36
21	Multiple cutaneous squamous cell carcinomas in a patient with interferon receptor 2 (IFNÂR2) deficiency. Journal of Medical Genetics, 2010, 47, 631-634.	1.5	33
22	Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461, 621-626.	13.7	213
23	A partial form of recessive STAT1 deficiency in humans. Journal of Clinical Investigation, 2009, 119, 1502-1514.	3.9	167
24	Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. Journal of Biotechnology, 2008, 136, S176.	1.9	0
25	Complementation of a pathogenic <i>IFNGR2</i> misfolding mutation with modifiers of N-glycosylation. Journal of Experimental Medicine, 2008, 205, 1729-1737.	4.2	59
26	IFN-Î ³ Mediates the Rejection of Haematopoietic Stem Cells in IFN-Î ³ R1-Deficient Hosts. PLoS Medicine, 2008, 5, e26.	3.9	67
27	Complementation of a pathogenicIFNGR2misfolding mutation with modifiers of N-glycosylation. Journal of Cell Biology, 2008, 182, i6-i6.	2.3	0
28	Corrigendum to "Inborn errors of IL-12/23- and IFN-γ-mediated immunity: Molecular, cellular, and clinical features―[Semin. Immunol. 18 (2006) 347–361]. Seminars in Immunology, 2007, 19, 136-137.	2.7	2
29	Gain-of-glycosylation mutations. Current Opinion in Genetics and Development, 2007, 17, 245-251.	1.5	65
30	BCG-osis and tuberculosis in a child with chronic granulomatous disease. Journal of Allergy and Clinical Immunology, 2007, 120, 32-38.	1.5	118
31	A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease. Journal of Medical Genetics, 2006, 44, e65-e65.	1.5	52
32	Inborn errors of IL-12/23- and IFN- \hat{l}^3 -mediated immunity: molecular, cellular, and clinical features. Seminars in Immunology, 2006, 18, 347-361.	2.7	422
33	Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease. PLoS Genetics, 2006, 2, e131.	1.5	171
34	X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. Journal of Experimental Medicine, 2006, 203, 1745-1759.	4.2	264
35	T Cell-Dependent Activation of Dendritic Cells Requires IL-12 and IFN- \hat{l}^3 Signaling in T Cells. Journal of Immunology, 2006, 177, 3625-3634.	0.4	35
36	Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nature Genetics, 2005, 37, 692-700.	9.4	198

#	Article	IF	CITATIONS
37	Inherited disorders of the IL-12-IFN-Î ³ axis in patients with disseminated BCG infection. European Journal of Pediatrics, 2005, 164, 753-757.	1.3	59